Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Antibody (immunoglobulin) (Ig (for immunoglobulin); no single abbreviation for "pathogen-specific antibody" as it describes a functional subset, not a unique molecule.)
- Target
- Ig (for immunoglobulin); no single abbreviation for "pathogen-specific antibody" as it describes a functional subset, not a unique molecule.
- Molecular classification
- Other (Immune effector protein – Immunoglobulin superfamily)
01
Overview
Antibodies (immunoglobulins) are Y-shaped glycoproteins produced by B lymphocytes of the adaptive immune system that specifically bind unique antigens, typically found on pathogens. Pathogen-specific antibodies are those that are generated in response to a particular infectious agent and recognize one or more of its antigens with high specificity. They confer immunity by neutralizing pathogens, promoting their elimination via opsonization and complement activation, and establishing immunological memory for rapid response upon re-exposure. Numerous monoclonal antibodies have been developed as therapeutics to target pathogen antigens in infectious and autoimmune diseases, but "pathogen-specific antibodies" is not the name of a single molecular entity, rather a functional description of the diverse antibodies generated to combat specific pathogens.
- Other names
- ImmunoglobulinAntibodyIgIgGIgMIgAIgEIgD
02
Mechanism of action
Neutralization of pathogens/toxins Opsonization for phagocytosis Complement-mediated lysis of pathogens Antibody-dependent cellular cytotoxicity (ADCC)
03
Biological functions
Immune responsePathogen neutralizationOpsonization (facilitating phagocytosis)Complement activationAntigen-specific memory
04
Disease associations
Infection (protective)Autoimmune disease (in certain contexts, e.g., autoantibodies)Inflammatory diseases (in the case of immune complex formation)
05
Safety considerations
Risk of serum sickness (with intravenous immunoglobulin)Hypersensitivity and allergic reactions (e.g., IgE-mediated)Potential for autoimmunity (pathogenic autoantibodies in diseases such as lupus, myasthenia gravis, etc.)
06
Interacting drugs
Therapeutic monoclonal antibodies (e.g., adalimumab, infliximab – but these are antibodies themselves)
2 more in the full profile.
07
Biomarkers
Measurement of pathogen-specific antibody titers (serology: e.g., anti-HIV Ab, anti-HBV Ab, anti-SARS-CoV-2 Ab) for diagnosis or monitoring immune status
Beyond the preview
Go deeper on Antibody (immunoglobulin) (Ig (for immunoglobulin); no single abbreviation for "pathogen-specific antibody" as it describes a functional subset, not a unique molecule.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Antibody (immunoglobulin) (Ig (for immunoglobulin); no single abbreviation for "pathogen-specific antibody" as it describes a functional subset, not a unique molecule.).